Urology Times Newsletter

To view this email as a web page, click here.

MEN’S HEALTH MONDAY

PSA adjustments are required in men taking 5-ARIs

"This report brings to light an often-suspected but previously undocumented clinical issue in great and alarming detail," writes Badar M. Mian, MD.

Read his column

Salvage LND may help delay recurrence

A preliminary study of the use of salvage lymph node dissection in patients with nonmetastatic, castration-resistant prostate cancer indicates the potential to delay disease recurrence as well as the use of systemic therapies through this approach.

Learn more

SURVEY

Is DRE still a relevant tool in the management of prostate cancer?

MORE FROM UROLOGY TIMES

Low T could hasten time to post-RP biochemical recurrence

Researchers develop noninvasive biomarker for aggressive PCa

Dr. Krambeck discusses a percutaneous nephrolithotomy procedure in a 54-year-old woman with a large upper pole stone completely obstructing the upper pole system. The patient was referred to her after undergoing a previous percutaneous stone removal in which, despite multiple percutaneous accesses into the kidney, the referring urologist was unable to advance a wire into the standard collecting system and down the ureter. Dr. Krambeck discusses the importance and benefits of utilizing the Perc-Tic technique, a percutaneous diverticulum access technique for this type of situation. She provides information on the devices and a step-by-step process to the technique required to circumvent the obstruction, remove the stone, and find/reopen the connection to the collecting system. Read it now.

JOB OPPORTUNITIES

NY-WNY Urology Associates

VT-University of Vermont

AUA’s new guidelines for benign prostatic hyperplasia

Read what an expert panel had to say about a recommendation to consider prostatic urethral lift for men with BPH, how to improve the care pathway for BPH, and more Read more .

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.